Daniel Nikcevich is a Hematology physician affiliated with Essentia Health. OpenAlex indexes 87 publications with 3,076 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment$68
- PFIZER INC.Program year20251 payment$26
- E.R. Squibb & Sons, L.L.C.Program year20221 payment$22
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.5%Aromatase Inhibitor8.8%Anastrozole79%Letrozole13%Exemestane9%Part D<11 patientsKinase inhibitor5.7%Imbruvica75%Imatinib Mesylate25%Part D<11 patients+ 6 more classes in this area
Nervous system
30%Opioid Agonist11.6%Oxycodone Hcl70%Hydromorphone Hcl16%Fentanyl8%Tramadol Hcl6%Part D<11 patientsPhenothiazine11.4%Prochlorperazine Maleate100%Part D≥98 patients+ 4 more classes in this area
Metabolism & gastrointestinal
13.5%Corticosteroid5.9%Prednisone100%Part D≥32 patientsSerotonin-3 Receptor Antagonist2.8%Ondansetron Hcl73%Ondansetron Odt27%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2005–2014 per NIH RePORTER. The latest:
- Duluth Community Clinical Oncology Program
Essentia Institute of Rural Health
FY2014$111,679U10CA035269 - Duluth Community Clinical Oncology Program
Essentia Institute of Rural Health
FY2013$770,073U10CA035269 - Duluth Community Clinical Oncology Program
Essentia Institute of Rural Health
FY2012$538,966U10CA035269
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
Breast Cancer Research and Treatment
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Gessert
Essentia Health
Nancy Sudak, MD
Essentia Health
Jesus Vera Aguilera, MD
Essentia Health
David C. Herman
Essentia Health
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Jeffrey Miller, MD
University of Minnesota Medical School
Faith Davies, MD
NYU Langone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”